Abstract Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achieved remarkable success in the treatment of hematopoietic malignancies, whether it can benefit solid tumor patients to the same extent is still uncertain. Even though hundreds of clinical trials are undergoing exploring a variety of tumor-associated antigens (TAA), no such antigen with comparable properties like CD19 has yet been identified regarding solid tumors CAR-T immunotherapy. Inefficient T cell trafficking, immunosuppressive tumor microenvironment, suboptimal antigen recognition specificity, and lack of safety control are currently considered as the main obstacles in solid tumor CAR-T therapy. Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results. We further discussed the challenges that CAR-T is facing for solid tumor treatment and proposed potential strategies to improve the efficacy of CAR-T as promising immunotherapy.

+More

solid tumor treatment hematopoietic suboptimal antigen recognition tumorassociated chimeric antigen receptor t cell cart therapy tumor cart clinical trials cell trafficking immunosuppressive tumor safety cell acute

Jian Li,Wenwen Li,Kejia Huang,Yang Zhang,Gary Kupfer,Qi Zhao,.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. 11 (1),.

Jian Li,Wenwen Li,Kejia Huang,Yang Zhang,Gary Kupfer,Qi Zhao,"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward" 11

Jian Li,Wenwen Li,Kejia Huang,Yang Zhang,Gary Kupfer,Qi Zhao,"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward"